|
Index | - | P/E | - | EPS (ttm) | -1.59 | Insider Own | 1.16% | Shs Outstand | 30.32M | Perf Week | 4.20% |
Market Cap | 1.39B | Forward P/E | - | EPS next Y | -2.14 | Insider Trans | 0.00% | Shs Float | 18.11M | Perf Month | 21.49% |
Income | -53.80M | PEG | - | EPS next Q | -0.46 | Inst Own | 97.00% | Short Float | 18.88% | Perf Quarter | 6.87% |
Sales | - | P/S | - | EPS this Y | -25.80% | Inst Trans | 28.49% | Short Ratio | 10.92 | Perf Half Y | 44.67% |
Book/sh | 6.08 | P/B | 5.96 | EPS next Y | 41.20% | ROA | - | Target Price | 44.14 | Perf Year | - |
Cash/sh | 4.87 | P/C | 7.44 | EPS next 5Y | - | ROE | - | 52W Range | 18.60 - 40.81 | Perf YTD | 7.06% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -11.20% | Beta | - |
Dividend % | - | Quick Ratio | 27.30 | Sales past 5Y | - | Gross Margin | - | 52W Low | 94.84% | ATR | 2.83 |
Employees | 60 | Current Ratio | 27.30 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 57.40 | Volatility | 10.31% 8.48% |
Optionable | Yes | Debt/Eq | 0.00 | EPS Q/Q | 75.00% | Profit Margin | - | Rel Volume | 0.75 | Prev Close | 34.29 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 313.07K | Price | 36.24 |
Recom | 1.60 | SMA20 | 6.98% | SMA50 | 6.18% | SMA200 | 26.11% | Volume | 233,374 | Change | 5.69% |
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers. Its lead product candidate is ORIC-101, a small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across various solid tumors. The company's second product candidate is ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens. It is also developing multiple precision medicines targeting other cancer resistance mechanisms. The company was founded in 2014 and is headquartered in South San Francisco, California. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in google |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite